The program, called BioMe, uses a new platform called “Clinical Implementation of Personalized Medicine through Electronic Health Records and Genomics” or CLIPMERGE to communicate with the EMR and give physicians real-time guidance based on a patient’s genetic profile. Currently, real-time feedback for therapies, based on DNA, is only available for cardiovascular disease, blood clots and high cholesterol.
More Articles on Mount Sinai Medical Center:
Mount Sinai Medical Center Promotes Alex Mendez to Executive VP, CFO
Mount Sinai Medical Center Unveils $440M Hess Center, New Logo
Spreading Ideas About Healthcare’s Future: Q&A With Dr. Kenneth Davis, President and CEO of The Mount Sinai Medical Center
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
